Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical (NASDAQ:COLL) in a research report report published on Friday, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently commented on COLL. Needham & Company LLC restated a buy rating and set a $33.00 target price (down previously from $35.00) on shares of Collegium Pharmaceutical in a research note on Wednesday, January 16th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a hold rating to a buy rating and set a $17.00 target price on the stock in a research note on Wednesday, January 9th. ValuEngine upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 3rd. SunTrust Banks initiated coverage on shares of Collegium Pharmaceutical in a research note on Tuesday, March 19th. They set a buy rating and a $22.00 target price on the stock. Finally, BidaskClub cut shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $28.67.

NASDAQ COLL opened at $14.66 on Friday. Collegium Pharmaceutical has a 12 month low of $13.10 and a 12 month high of $28.91. The company has a market cap of $553.61 million, a price-to-earnings ratio of -12.32 and a beta of 0.32. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 0.11.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.65. Collegium Pharmaceutical had a negative net margin of 13.95% and a negative return on equity of 41.12%. The company had revenue of $73.40 million for the quarter, compared to analysts’ expectations of $72.71 million. During the same quarter last year, the business earned ($0.54) EPS. The firm’s revenue was up 579.6% compared to the same quarter last year. As a group, analysts expect that Collegium Pharmaceutical will post -0.25 earnings per share for the current year.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $17.17, for a total transaction of $429,250.00. Following the sale, the director now owns 227,362 shares in the company, valued at $3,903,805.54. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 8.08% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Morgan Stanley increased its position in Collegium Pharmaceutical by 20.1% in the third quarter. Morgan Stanley now owns 1,056,133 shares of the specialty pharmaceutical company’s stock worth $15,566,000 after purchasing an additional 176,577 shares during the last quarter. LPL Financial LLC increased its position in Collegium Pharmaceutical by 4.5% in the third quarter. LPL Financial LLC now owns 200,863 shares of the specialty pharmaceutical company’s stock worth $2,961,000 after purchasing an additional 8,558 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in Collegium Pharmaceutical by 4.8% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock worth $247,000 after purchasing an additional 655 shares during the last quarter. Monarch Partners Asset Management LLC boosted its stake in Collegium Pharmaceutical by 19.2% during the fourth quarter. Monarch Partners Asset Management LLC now owns 33,770 shares of the specialty pharmaceutical company’s stock worth $580,000 after buying an additional 5,430 shares during the period. Finally, MetLife Investment Advisors LLC purchased a new position in Collegium Pharmaceutical during the third quarter worth $339,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

See Also: Cost of Equity

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.